A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advan
- PDF / 1,275,952 Bytes
- 20 Pages / 595.276 x 790.866 pts Page_size
- 35 Downloads / 173 Views
ORIGINAL RESEARCH
A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer Rana R. McKay . Jason M. Hafron . Christine Ferro . Helen M. Wilfehrt . Kate Fitch . Scott C. Flanders . Michael D. Fabrizio . Michael T. Schweizer
Received: August 1, 2020 / Accepted: September 16, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Since sipuleucel-T approval in 2010, the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) now includes the androgen-receptor signaling pathway inhibitors (ASPIs) abiraterone acetate or enzalutamide. In 2013 and 2014, these oral agents were approved for use in men with metastatic prostate cancer who had minimal to no symptoms. We compared overall survival (OS) in men who received their first mCRPC treatment using the Medicare Fee-for-Service
Electronic Supplementary Material The online version of this article (https://doi.org/10.1007/s12325020-01509-5) contains supplementary material, which is available to authorized users. R. R. McKay (&) Moores Cancer Center, University of California San Diego, San Diego, CA, USA e-mail: [email protected] J. M. Hafron William Beaumont School of Medicine, Oakland University, Auburn Hills, MI, USA C. Ferro K. Fitch Milliman Inc, New York, NY, USA H. M. Wilfehrt S. C. Flanders Department of Medical Affairs, Dendreon Pharmaceuticals, LLC, Seattle, WA, USA
100% administrative claims research dataset with patient-level linkage to the National Death Index. Methods: This retrospective cohort analysis (January 2013 to December 2017) included men who were chemo-naı¨ve at treatment start in 2014 and who had continuous Medicare Parts A, B, and D eligibility during the 3-year observation period. We compared: first-line sipuleucel-T vs. first-line ASPIs and any-line sipuleucel-T vs. any-line ASPIs (without sipuleucel-T). We used a multivariable regression model to help control for potentially confounding factors while assessing survival outcomes. Results: The model included 6044 eligible men (average age 75–78 years) with similar disease severity; [ 80% were white. Median OS, presented as sipuleucel-T vs. ASPI, was 35.2 vs.
M. D. Fabrizio Department of Urology, Eastern Virginia Medical School, Virginia Beach, VA, USA M. D. Fabrizio Urology of Virginia, PLLC, Virginia Beach, VA, USA M. T. Schweizer Division of Medical Oncology, University of Washington, Seattle, WA, USA M. T. Schweizer Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Adv Ther
20.7 months (n, 906 vs. 5092; any-line cohort) and 34.9 vs. 21.0 months (n, 647 vs. 4810; firstline cohort). Model outcomes indicated sipuleucel-T was associated with significantly prolonged OS compared with ASPIs: adjusted hazard ratio, 0.59 (95% CI 0.527–0.651) and 0.56 (0.494–0.627) for the any-line and first-line cohorts, respectively. Conclusion: This analysis suggests use of sipuleucel-T at any time was associated with improved OS compared with ASPI use alone. Of note, these a
Data Loading...
